✦ LIBER ✦

Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small-cell lung cancer

✍ Scribed by Cesare Gridelli; Giuseppe Airoma; Pasquale Incoronato; Rosario Pepe; Giovanni Palazzolo; Antonio Rossi; Angelo Raffaele Bianco

Publisher: Springer
Year: 1992
Tongue: English
Weight: 275 KB
Volume: 30
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00686314

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized study of two vindesine plus

A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer

✍ R. Rosell; A. Abad-Esteve; I. Moreno; A. Barnadas; J. Carles; C. Fernandez; N. R 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 726 KB

Alternated approach with local irradiati

Alternated approach with local irradiation and combination chemotherapy including cisplatin or carboplatin plus epirubicin and etoposide in intermediate stage non-small cell lung cancer

✍ Cécile le Péchoux; Rodrigo Arriagada; Thierry Le Chevalier 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 226 KB 👁 2 views

Alternated approach with local irradiati

Alternated approach with local irradiation and combination chemotherapy including cisplatin or carboplatin plus epirubicin and etoposide in intermediate stage non-small cell lung cancer

✍ Pasquale Cornella; Gianfranco Scoppa; Antonio Daponte; Gennaro Musefta; Caterina 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 752 KB

Background. Prognosis of unresectable non-small cell lung cancer (NSCLC) patients is disappointing: their median survival time does not exceed 8-12 months. Recently, some authors reported an increased response rate and sometimes a prolonged survival for patients with intrathoracic disease treated wi

Phase II study of cisplatin as a 5-day c

Phase II study of cisplatin as a 5-day continuous infusion with vindesine plus recombinant human granulocyte-colony-stimulating factor in the treatment of advanced non-small-cell lung cancer

✍ Yoshikuni Saito; Kiyoshi Mori; Keigo Tominaga; Kouhei Yokoi; Naoto Miyazawa 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 500 KB